8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Feb 7, 2007)

Filed February 7, 2007For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. filed an 8-K on February 7, 2007, to report its financial results for the fourth quarter and full year ended December 31, 2006. While the filing itself is primarily a notification of the earnings release, the attached press release (Exhibit 99.1) contains the detailed financial and operational updates for investors. Investors should refer to the press release for comprehensive information regarding the company's performance, strategic progress, and financial condition as of that date. The primary purpose of this filing is to provide public access to Alnylam's most recent financial performance data. This includes key metrics such as revenue, net income/loss, earnings per share, and cash position, as well as any significant operational achievements or challenges encountered during the reporting period. Understanding these results is crucial for investors to assess the company's trajectory and make informed investment decisions.

Key Highlights

  • 1Filing announces financial results for the quarter and year ended December 31, 2006.
  • 2The press release containing the financial results is furnished as Exhibit 99.1.
  • 3The filing serves as notification of the earnings announcement.
  • 4Information is deemed furnished, not filed, for purposes of Section 18 of the Exchange Act.
  • 5Key financial metrics and operational updates are contained within the accompanying press release.
  • 6CEO John M. Maraganore signed the report.
  • 7Date of earliest event reported is February 7, 2007.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Alnylam Pharmaceuticals, Inc.'s financial results for the fourth quarter and the full year ended December 31, 2006. The detailed financial information is provided in an attached press release.

The actual financial results and operational details are located in the press release dated February 7, 2007, which is furnished as Exhibit 99.1 to this Form 8-K filing.

No, the information in this Form 8-K, including the attached press release, is furnished, not filed. This means it is not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference into another filing.

The report was signed by John M. Maraganore, President and Chief Executive Officer of Alnylam Pharmaceuticals, Inc.